23:38 , Jan 18, 2019 |  BC Extra  |  Politics & Policy

Winners of China's centralized procurement to secure over 60% market share

Companies that won tender bids for China's pilot program for centralized procurement of generic drugs will be guaranteed a market share of 60-70% when the implementation phase begins in late March. China’s State Council approved...
22:43 , Dec 7, 2018 |  BC Extra  |  Politics & Policy

China releases final results of centralized procurement bids

China's Joint Procurement Office released the final results of its centralized procurement pilot program Friday, in which winning bidders agreed to price cuts up to about 90% for 25 generics. State-owned Shanghai Securities News reported...
19:00 , Dec 7, 2018 |  BC Week In Review  |  Company News

Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Dec. 6 in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected. State-owned Shanghai Securities News reported...
01:15 , Dec 7, 2018 |  BC Extra  |  Company News

Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Thursday in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected. State-owned Shanghai Securities News reported significantly...
18:16 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Early data for Enyo's HBV, NASH candidate tee up Phase II

Enyo Pharma S.A. (Lyon, France) said once-daily oral EYP001 for four weeks was well tolerated with no off-target effects or serious adverse events reported in a Phase Ib trial to treat chronic HBV infection. The...
15:19 , May 4, 2018 |  BC Week In Review  |  Clinical News

Altimmune evaluating next steps for HBV vaccine

Altimmune Inc. (NASDAQ:ALT) said HepTcell (FP-02.2) given on days one, 29 and 57 as an add-on to entecavir or tenofovir was well tolerated but led to "inconclusive" T cell immunogenicity results in a Phase Ib...
22:21 , Oct 12, 2017 |  BC Innovations  |  Targets & Mechanisms

Mining the negatives

By investigating why its discontinued siRNA candidate against hepatitis B caused only weak responses in certain patients, Arrowhead Pharmaceuticals Inc. has upended a dogma about the virus’ genetics that has been clouding drug design and...
22:34 , Sep 28, 2017 |  BC Extra  |  Preclinical News

Arrowhead paper reveals additional HBV antigen source

A paper published in Science Translational Medicine by researchers at Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) and colleagues discovered that hepatitis B surface antigen (HBsAg) is expressed from HBV DNA transcripts integrated into the host genome in...
19:25 , Jul 31, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Cell models A high throughput cell co-culture system could be used to screen therapies for HBV infection. The system utilizes a microwell plate for simultaneously generating up to 96 co-cultures of pooled primary human...
21:22 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

ARC-520: Ph IIb hold

Arrowhead said FDA placed a clinical hold on the double-blind, placebo-controlled, U.S. Phase IIb Heparc-2004 trial of IV ARC-520. Arrowhead said FDA placed the hold after deaths occurred in a non-human primate toxicology study in...